NOTICE 1 페이지

NEWS & EVENT

Total 12 - 1 page

No	Subject	Date	Hit
12	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	8,519
익명 8,519 2021.07.15
11	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	4,731
익명 4,731 2024.02.27
10	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	4,384
익명 4,384 2024.10.07
9	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	3,997
익명 3,997 2025.06.14
8	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	3,838
익명 3,838 2022.11.09
7	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	3,733
익명 3,733 2024.05.21
6	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	3,727
익명 3,727 2025.03.31
5	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	3,430
익명 3,430 2024.07.10
4	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	3,422
익명 3,422 2025.02.13
3	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	2,866
익명 2,866 2024.11.21
2	신주발행공고	2026.03.12	2,430
익명 2,430 2026.03.12
1	신주발행공고	2025.12.29	1,930
익명 1,930 2025.12.29

1페이지

INVESTORS & MEDIA

INVESTORS & MEDIA

NEWS & EVENT